To inhibit the PI3K pathway, we used multiple approaches and found that cell viability of primary Trim24COE metaplastic carcinosarcoma cells was reduced in a dose-dependent manner by inhibiting either c-MET, with Critzotinib and PHA-665752, or PI3K/mTOR, with dual inhibitor Dactolisib. The gene discussed is MET; the disease is carcinosarcoma.